Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
COGT- The offering was made to two new fundamental institutional investors -
August 28, 2025Capital Raise
Read more →JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $25
COGTMay 29, 2025
Read more →HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Lowers Price Target to $12
COGTMay 20, 2025
Read more →Baird Maintains Neutral on Cogent Biosciences, Lowers Price Target to $7
COGTMay 7, 2025
Read more →Cogent Biosciences Q1 EPS $(0.52) Beats $(0.61) Estimate
COGTMay 6, 2025
Read more →Cogent Biosciences Announces It Will Present Four Posters At American Association For Cancer Research Annual Meeting 2025 , April 25-30 In Chicago, Illinois
COGTApril 25, 2025
Read more →Scotiabank Initiates Coverage On Cogent Biosciences with Sector Outperform Rating, Announces Price Target of $17
COGTMarch 7, 2025
Read more →Cogent Biosciences Announces SUMMIT Continues To Showcase Powerful Symptomatic Improvement In NonAdvanced Systemic Mastocytosis Patients; 65% Mean Improvement In Total Symptom Score At 48 Weeks, Including 88% Of Patients Achieving At Least A 50% Reduction
COGTFebruary 27, 2025
Read more →Baird Maintains Neutral on Cogent Biosciences, Lowers Price Target to $8
COGTFebruary 27, 2025
Read more →Needham Reiterates Hold on Cogent Biosciencesto Hold
COGTFebruary 26, 2025
Read more →HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Lowers Price Target to $14
COGTJanuary 14, 2025
Read more →Cogent Biosciences Announces 2025 Milestones, SUMMIT Results In NonAdvSM In July, PEAK Phase 3 In 2nd-Line GIST By Year-End, APEX In AdvSM in H2; Presenting at J.P. Morgan Healthcare Conference Tomorrow At 10:30 AM ET
COGTJanuary 13, 2025
Read more →JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $21
COGTNovember 14, 2024
Read more →Cogent Biosciences Announces Bezuclastinib Presentations At The 66th Annual American Society of Hematology Meeting
COGTNovember 5, 2024
Read more →HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $17 Price Target
COGTNovember 4, 2024
Read more →